Clinical trials: Checkpoint Inhibitor
Immune-related Adverse Event
Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events
This project investigates immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs), focusing on metabolic changes.
- Trial name
- DNP_irAE (NCT06243250)
- Testing
- Hyperpolarized 13C-MRI
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Arrhythmia, Long QT Syndrome
AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis
ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data.
- Conditions
- Arrhythmia, Long QT Syndrome, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- ELDORA (NCT07644715)
- Where
- France
- Volunteers
- 127,000 people, healthy volunteers welcome
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Melanoma
Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor
This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune…
- Trial name
- NCT07660666
- Testing
- Electronic Health Record Review, Internet-Based Intervention, Patient Navigation
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
LAG3 Expression in Triple Negative Breast Cancer
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
- Trial name
- NCT06259162
- Testing
- LAG-3 expression / immune checkpoint protein expression
- Where
- South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
- Trial name
- NCT05451173
- Testing
- Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Alexander Chi
Non-small Cell Lung Cancer, Radiotherapy Side Effect
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer.
- Trial name
- NCT05269485
- Testing
- High-dose hypofractionated radiotherapy, Low-dose hypofractionated radiotherapy
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
This is a blood collection study being conducted to better understand and describe the immunological blood profile changes in patients with advanced non small cell lung cancer undergoing treatment with checkpoint inhibitor…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Healthy
- Trial name
- NCT04187768
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Indiana University
Melanoma, Renal Cancer
Microbiome Immunotherapy Toxicity and Response Evaluation
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
- Conditions
- Melanoma, Renal Cancer, Lung Cancer
- Trial name
- NCT04107168
- Testing
- Nivolumab, Pembrolizumab, Ipilimumab
- Where
- 13 sites in United Kingdom
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- CCTU- Cancer Theme
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.
- Conditions
- Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Immune Checkpoint Inhibitor
- Trial name
- LILIPSY (NCT05810402)
- Testing
- Liquid Biopsy
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
NSCLC Associated With Leptomeningeal Metastases
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
This is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with…
- Trial name
- NCT06132698
- Testing
- Tislelizumab or pembrolizumab, pemetrexed
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer, Colorectal Cancer
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the…
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
- Trial name
- NCT04638751
- Testing
- Immunotherapy, Chemotherapy, CRC surgical resection
- Where
- 10 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Melanoma, Non-small Cell Lung Cancer (NSCLC)
Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy
Background of the study: Immune checkpoint inhibitors (ICIs) are widely used as treatment for multiple cancer types and the number of patients with longterm disease control after ICIs is increasing.
- Conditions
- Melanoma, Non-small Cell Lung Cancer (NSCLC), Urogenital Cancers
- Trial name
- TasteSPICIER (NCT06495008)
- Testing
- no intervention, only questionnaires, saliva collection and taste/smell tests
- Where
- Netherlands
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen